Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Year-end Report 1 January to 31 December 2018

Summary of the year-end reportFinancial year (1 January to 31 December 2018) · Operating revenue KSEK 1 (0) · Income after financial items KSEK -15 434 (-8 824) · Earnings per share -0,41 (-0,50) · Cash and cash equivalents as of 31 December 2018 KSEK 38 716 (33 357) · Equity ratio as of 31 December 2018 93,2 (90,4) % Fourth Quarter (1 October to 31 December 2018) · Operating revenue KSEK 1 (0) · Income after financial items KSEK -4 534 (-3 231) · Earnings per share -0,12 (-0,18) Significant events during the fourth quarter of 2018 · The company

CEO Robin Lindahl to leave Normet and join Taaleri

Robin Lindahl, President and CEO of Normet Group has decided to leave Normet.  He will join Taaleri plc as their new CEO latest 1.8.2019. Taaleri is listed on the Helsinki Stock Exchange and its business comprises of wealth management, financial services and renewable energy business.The search for a new President and CEO has already started and Mr. Lindahl will be actively supporting in the transfer of his duties forward over the coming months. “It has been a real pleasure leading Normet as CEO during the last 3 years. I will mostly miss the great team and the skilled colleagues at

Humana reports fourth quarter and full year results 2018

High organic growth and a Nordic care group in the making Fourth quarter, October-December 2018:  ·  Operating revenue was SEK 1,700 M (1,616), an increase of 5%. ·  Operating profit was SEK 82 M (SEK 66 M), an increase of 24 % or SEK 16 M. Excluding acquisition related costs, operating profit increased by 42% to SEK 95 M (67) for the period. ·  Net profit after tax for the period was SEK 51 M (34).   ·  Earnings per share for the period before and after dilution were SEK 0.97 (0.63).   ·  Operating cash flow was SEK 136 M (197).   Full year, January-December 2018

Sören Mellstig proposed as new Chairman of the Board of Humana

Ahead of the Annual General Meeting 2019 the Nomination Committee of Humana AB has decided to propose Sören Mellstig as the new Chairman of the Board.The Chairman of the Board, Per Båtelson, has after eleven years as a board member, including five years as its Chairman, declared that he is not available for re-election. The Nomination Committee has therefore decided to propose to the Annual General Meeting the election of Sören Mellstig as the new Chairman of the Board. Sören Mellstig is Chairman of Cellavision, Ellevio and Rkliniken, and Industrial Partner and co-founder of Impilo, one

AstraZeneca Full-Year and Q4 2018 Results

AstraZeneca PLC  14 February 2019 07:00 GMT     Full-year and Q4 2018 results  New launches and commercial execution deliver full-year sales growth and a very strong final quarter.  2019 anticipated to be a year of higher year-on-year sales growth combined with operating leverage.     The final quarter of the year saw a very strong performance, including Product Sales growth of 5% (8% at CER1) to $5,768m. In the year, Product Sales increased by 4% to $21,049m, reflecting the performance of new medicines2 (+81%) and the sustained strength of Emerging Markets (+12%, +13%

Attendo’s year-end report 2018 - Strong growth in own operations affects margins

Attendo continues to show strong growth in own operations, with a record number of new nursing home openings in the full year 2018. The combination of a high pace of openings and costs related to closing down other operations puts pressure on profitability. The possibilities to increase margins from current level is deemed limited during the current year and 2020.CEO and President Martin Tivéus comments on the report: “Continued growth in own operations Attendo demonstrated high growth in the fourth quarter and for the full year of 2018, a result of a record-high number of new homes

Proposal by the Nomination Committee regarding the Board of Directors of Cloetta AB

Cloetta’s Nomination Committee has informed the company of its proposal regarding new Board of Directors.The Nomination Committee proposes re-election of the current directors Lilian Fossum Biner, Mikael Aru, Lottie Knutson, Alan McLean Raleigh, Camilla Svenfelt and Mikael Svenfelt. Mikael Norman has declined re-election. Lilian Fossum Biner is proposed to be re-elected as the Chairman of the Board of Directors. Furthermore, the Nomination Committee proposes Patrick Bergander as new director. Patrick Bergander is since 2014 CEO of RSA Scandinavia (Codan/Trygg-Hansa) and has also been

Alligator Bioscience AB Year-end Report 2018

The bispecific drug candidate ATOR-1015 in clinical developmentSignificant events October-December• The Swedish MPA (Medical Products Agency) approved start of Phase I clinical trial of ATOR-1015.• New preclinical data for ATOR-1017 and ALG.APV-527 presented at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC).• The company expanded its pipeline and initiated preclinical development of the ATOR-1144 drug candidate.• Research funding granted from Vinnova.• Alligator Bioscience recorded a revenue of approximately USD 3 million related to a collaboration with

Summons to the Annual General Meeting of shareholders in Castellum AB (publ)

The shareholders of Castellum AB (publ), Reg. No. 556475-5550, are hereby summoned to the Annual General Meeting to be held on Thursday, March 21, 2019 at 5 pm in RunAn, Chalmers Kårhus, Chalmersplatsen 1, Gothenburg. The entrance opens at 4 pm.Notification etcShareholders wishing to attend the Annual General Meeting must be registered as share­holders in the share register kept by Euroclear Sweden AB by Friday, March 15, 2019 and must also have notified their attendance to the company no later than Friday, March 15, 2019 (pre­ferably before 4 pm).   Notification of attendance at the

European High Growth Opportunities Securitization Fund requests conversion of convertible bonds

European High Growth Opportunities Securitization Fund has by notice to the board of directors of QuickCool AB (Publ) ("QuickCool") called upon its right to conversion of convertible bonds previously issued in accordance with the financing solution announced by QuickCool through a press release on 21 June 2018.QuickCool has received notification from European High Growth Opportunities Securitization Fund regarding conversion of convertible bonds into 500 000 shares in QuickCool, corresponding to SEK 300 000 of the convertible loan. The conversion price per share is SEK 0,60. Upon

Eltel Group: Full-year report January–December 2018

October–December 2018 ·Net sales EUR 330.9 million (374.2). Total growth -11.6% and organic growth* in Power and Communication -5.1% ·Operative EBITA** EUR 2.9 million (2.2) and operative EBITA margin 0.9% (0.6) ·Operating result (EBIT) EUR -0.2 million (1.2) and EBIT margin -0.1% (0.3) ·Net result EUR -3.3 million (-7.7) ·Earnings per share EUR -0.02 (-0.05), basic and diluted ·Cash flow from operating activities EUR 70.0 million (42.3) January–December 2018 · Net sales EUR 1,188.9 million (1,329.9). Total growth -10.6% and organic growth*

Wihlborgs signs agreement with voestalpine Böhler weldCare AB to build new production facility in Malmö

Wihlborgs has signed a 15-year lease with voestalpine Böhler weldCare AB for 4,300 m². The lease will be used for a production facility of voestalpine Böhler weldCare AB that Wihlborgs will build at the Stenåldern 7 property in Fosie, Malmö.voestalpine Böhler weldCare AB is part of the voestalpine Böhler Welding Group, a leading manufacturer and worldwide supplier of filler metals for industrial welding and brazing applications. The lease from Wihlborgs is dedicated to a new state-of-the-art facility for the production of premium finishing chemicals of voestalpine Böhler weldCare AB.

InCoax appoints Håkan Rusk CSMO

Håkan Rusk has been appointed Chief Sales and Marketing Officer at InCoax and will play a critical role in the growth journey of the company.Håkan Rusk who joined InCoax as Chief Marketing Officer in September 2018, with approximately 24 years’ working experience in IT, telecommunications and application markets, has been appointed Chief Sales and Marketing Officer with immediate effect. Håkan Rusk will report to Peter Carlsson, CEO. Håkan Rusk has previously been the Director of Sales Management at Fingerprint Card AB 2013-2018, where he lead the work to scale the sales operations

BIMobject: Year-End Report and Interim Report  October – December 2018

The complete report is available on the Company’s website info.bimobject.com. Fourth quarter 2018 ·  Billing increased by 7 percent to SEK 59 (55) million. ·  The Group’s net sales increased by 2 percent to SEK 39 (38) million. The distribution between projects and web services (subscriptions) was 42/58 (44/56) percent. ·  The Group’s operating profit/loss amounted to SEK -34 (-4) million. ·  Basic earnings per share amounted to SEK -0.26 (-0.10). ·  Cash flow from operating activities was SEK -22 (-19) million. ·  The accumulated number of users increased to

IRRAS AB (PUBL) YEAR-END REPORT JANUARY–DECEMBER 2018

IRRAflow® launch initiated in the USFourth quarter, October–December 2018 · Net revenue totaled SEK 0.0 million (0.7). · Operating loss (EBIT) amounted to SEK -50.1 million (-23.7). · Loss after tax totaled SEK -50.1 million (-23.2). · Earnings per share before and after dilution amounted to SEK -2.09 (-1.09). Period January–December 2018 · Net revenue totaled SEK 6.0 million (12.0). · Operating loss (EBIT) amounted to SEK -143.3 million (-61.5). · Loss after tax totaled SEK -138.8 million (-60.9). · Earnings per share before and after dilution amounted to SEK

Camurus to present at the Cowen and Company Annual Healthcare Conference 2019

Lund, Sweden — 14 February 2019 — Camurus (NASDAQ STO: CAMX) today announces that Fredrik Tiberg, President and CEO, will provide an overview and update on the company's business at the Cowen and Company 39th Annual Healthcare Conference in Boston, Massachusetts. The presentation will take place on Monday 11 March 2019 at 4:10 pm Eastern Standard Time and can be accessed via a live webcast at Camurus website www.camurus.com. An archived version of the webcast will be available for 30 days after the event. About CamurusCamurus is a Swedish science-led biopharmaceutical company committed

Full Year Report January – December 2018

BioArctic’s partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer’s disease. AbbVie in-licensed the Parkinson portfolioOctober – December 2018 · Net revenues for the period amounted to SEK 515.3 million (51.0) · Operating profit amounted to SEK 430.3 million (14.7) · Profit for the period amounted to SEK 335.2 million (11.8) · Earnings per share were SEK 3.81 (0.16) · Cash flow from operating activities amounted to SEK -89.3 million (-45.7) January – December 2018 · Net revenues for the period amounted to SEK 714.0 million (140.7) ·

Kesko’s sales in January

The sales of Kesko Group’s continuing operations in January 2019 totalled €809.2 million and were at the previous year's level in comparable terms. The change in reported sales from continuing operations was -0.7%. "Sales grew in the grocery trade and in the building and technical trade. In the car trade, sales decreased due to the implementation of the WLTP emissions testing and the resulting delays in car deliveries," says Mikko Helander, Kesko’s President and CEO. Sales in the grocery trade totalled €418.9 million in January, an increase of 2.8% in comparable terms. Sales

Revenio Group Corporation: Financial Statement Bulletin, January 1 - December 31, 2018

Stock Exchange Release February 14, 2019 Financial Statement Bulletin at 9.00 am This release is a summary of Revenio Group’s January-December 2018 financial statement bulletin. The complete report is attached to this release as a pdf-file. The stock exchange release is also available on the company’s website at www.reveniogroup.fi/en.2018: Strong growth and profitability continued  October-December 2018 in brief   · Net sales totaled EUR 8.7 (7.6) million, showing an increase of 13.8% · Operating profit was EUR 3.0 (1.7) million, representing 34.8% of net sales, an increase

Stora Enso shares converted

STORA ENSO OYJ STOCK EXCHANGE RELEASE 14 February 2019 at 9.00 EETDuring the 1–31 January 2019 conversion period there was one conversion and a total of 53 236 A shares were converted into R shares. The shares were recorded in the Finnish trade register today, 14 February 2019, and trading in the new R shares will start on 15 February 2019.Breakdown of shares after conversion: A shares 176 259 436R shares 612 360 551Total 788 619 987 Each A share and each ten R shares carry one vote. The total amount of votes after the conversion is at least 237 495 491.For further

FONDIA’S REVENUE INCREASED BY 15.9 % DUE TO GOOD DEMAND FOR LDAAS SERVICE

FONDIA’S REVENUE INCREASED BY 15.9 % DUE TO GOOD DEMAND FOR LDAAS SERVICE Unless otherwise stated, the figures in parentheses refer to the corresponding period of the previous year. Jansson & Norin AB, aquired by Fondia during the financial period is reported as a part of Fondia as from 1.2.2018. July­–December 2018 in brief: · Net sales of 9.5 million (8.6), growth 10.7 %. · Operating profit (EBIT) was 0.5 million (1.1), change -54.7 %. Operating margin was 5.5 % (13.3). · Profit for the period was 0.4 million (0.9), change -59.1 %. · Recurring monthly invoicing

Eastnine to acquire S7 in Vilnius

- Purchase price EUR 128.3m Eastnine AB (publ) is pleased to announce that it has signed an agreement to acquire Building I, II and III of S7, a newly built and sustainable A-class office park in Vilnius’ central business district. Acquisition of Building I was closed simultaneously. The properties have a total leasable area of 42,500 sqm, 1,250 underground parking spaces and are fully leased to Telia Lietuva and Danske Bank Global Services Lithuania with an average duration of 6.4 years. The total transaction value amounts to EUR 128.3m, representing a yield of 5.8%.S7 office park

Nexam Chemical Holding AB (publ) Year-End Report 1 January – 31 December 2018

Increased activities during the yearFourth quarter at a glance Operational: ·Breakthrough with 10 MSEK order from one of the largest manufacturers of PET-foam. ·New product launched within high performance segment and a first order received. ·Production facility in St Andrews break production record. ·Completed automation project in Lomma increase production capacity. ·Water approval for pipes containing Nexam Chemical technology. ·New head of development recruited. Financials: ·Net sales for the fourth quarter totaled SEK 29,547,000 (9,

Terveystalo Plc: Terveystalo Group Financial Statements Bulletin 2018

Terveystalo Plc Stock Exchange Release 14 February 2019 at 9:00 EET Record year, strong platform for growth October-December 2018 in brief · Revenue increased by 4.2 percent year-on-year to EUR 197.9 million (189.9) · Adjusted* EBITDA increased by 11.9 percent year-on-year to EUR 32.5 million (29.1) · EBITDA increased by 7.2 percent year-on-year to EUR 26.6 million (24.8) · Adjusted* earnings before interest, taxes and amortization (EBITA) were 13.7 percent (12.6) of revenue · Earnings before interest, taxes and amortization (EBITA) were10.7 (10.3) percent of

There are no items matching the current filter
There are no more items matching the current filter
Back to top